EMEA-001858-PIP02-16-M03
Key facts
| Invented name |
Vyxeos liposomal (previously known as Vyxeos)
|
| Active substance |
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0292/2019
|
| PIP number |
EMEA-001858-PIP02-16-M03
|
| Pharmaceutical form(s) |
Powder for concentrate for infusion
|
| Condition(s) / indication(s) |
Treatment of acute myeloid leukaemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Jazz Pharmaceuticals Ireland Limited
E-mail: michael.chiarella@jazzpharma.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|